Lataa...

Single Institution Experience of Ipilimumab 3 mg/kg with Sargramostim (GM-CSF) in Metastatic Melanoma

Ipilimumab (IPI) 10 mg/kg with sargramostim (GM-CSF; GM) improved overall survival (OS) and safety of patients with advanced melanoma over IPI in a randomized phase II trial. The FDA-approved dose of IPI 3 mg/kg has not been assessed with GM (IPI-GM). Consecutive patients treated with IPI-GM at a si...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Cancer Immunol Res
Päätekijät: Luke, Jason J., Donahue, Hilary, Nishino, Mizuki, Giobbie-Hurder, Anita, Davis, Meredith, Bailey, Nancy, Ott, Patrick A., Hodi, F. Stephen
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2015
Aiheet:
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4561189/
https://ncbi.nlm.nih.gov/pubmed/25943535
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2326-6066.CIR-15-0066
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!